Navigation Links
Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
Date:5/18/2010

ed's progress and am impressed with the significant advances that the company has made in developing its novel oral insulin capsule, ORMD-0801," said Dr. Berelowitz. "I am very pleased to join Oramed's Board of Directors and look forward to working with the leadership team to enhance the development of therapeutic applications of the company's oral drug delivery technology and in the further maturation of ORMD-0801."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, t
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
2. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
3. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
5. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
10. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
11. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... 30, 2015   Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients ... reported financial results for the second quarter 2015. ... we remain on track to achieve our commercial and ... Officer of the Company. "Since our last quarterly earnings ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... expressing green fluorescent protein (GFP) in their retina cells ... video cameras, creating a real time computer record of ... the open access journal BMC Biotechnology , will ... and aging. , John Tower led a team of ...
... for Equipment and Service Excellence at the 54th Annual ... , IRVINE, Calif., Dec. 16 Masimo ... CO-Oximetry and Measure-Through-Motion and Low-Perfusion pulse oximetry, announced that ... notification system, Masimo Patient SafetyNet, was featured in a ...
... , - BiomarkerCenter of Excellence Established in ... 16 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: ... that it has purchased a minority equity stake in Caprion Proteomics, ... further enhance its biomarker service offerings to clients. , ...
Cached Biology Technology:AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 2AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 3AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 4AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 5Covance Purchases Equity Stake in Caprion Proteomics 2Covance Purchases Equity Stake in Caprion Proteomics 3Covance Purchases Equity Stake in Caprion Proteomics 4Covance Purchases Equity Stake in Caprion Proteomics 5
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... have also calculated that the bite force of the ... Carcharodon megalodon (also known as Big Tooth) is ... most formidable carnivore ever to have existed. Shark ... University, NSW Department of Primary Industries Fisheries (Australia) and ...
... the history of science and technology, there is ... technology developments converge that make it possible to ... biology, biomechanics and astrobiology with more recent developments ... are now well established in the lexicon of ...
... French colonial-style exterior of the National Cancer Hospital in Hanoi, ... hospitals crowded wards, treatment rooms and corridors, doctors are struggling ... the disease is winning. Each year in this country ... cancer and another 150,000 new cases are diagnosed. Figures are ...
Cached Biology News:Great white's mighty bite revealed 2The emerging scientific discipline of aeroecology 2In Vietnam, alongside progress, a battle for life 2In Vietnam, alongside progress, a battle for life 3
... for automated bioresearch: Developed for a ... Based on decades of experience in ... for bioresearch • Holographic gratings for ... and ease-of-use • Pulsed Xenon lamp ...
... GenePix Pro is the industry standard microarray ... combination of imaging and analysis tools, visualizations, ... GenePix Pro is included with every GenePix ... from third-party scanners and all types of ...
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... Sigma-Genosys offers custom peptide synthesis with a ... to best fit your research needs. ... Yield: 2mg-1g Sequence Length: ... Biotin, Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, ...
Biology Products: